TELA Bio, Inc. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On September 15, 2026, TELA Bio received notice of failure to satisfy Nasdaq continued listing standards, triggering Item 3.01 disclosure. The filing provides no details on the specific listing rule violated, remediation timeline, or company response. This is a critical regulatory event for a $76.8M market-cap company.
Why this rating
Delisting notice threatens public market status and access to capital for small-cap biomedical device company. Existential regulatory threat.
Extracted items
Price action (we called it negative)
before filing · preread $1.25 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.